Protara Therapeutics (TARA) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Differentiation and strategy

• Focus on reviving previously explored mechanisms with modern science and regulatory approaches.

• Emphasis on de-risked, mid- to late-stage assets with extensive prior data.

• Worldwide rights (excluding Japan) allow broad indication and geographic flexibility.

• Systemic administration capability sets the product apart from competitors.

• Ease of administration supports adoption in community settings.

TARA-002 and NMIBC program

• TARA-002 is a bacterial immunotherapy with a long safety record in Japan.

• Preliminary data in NMIBC showed 43%-50% complete response at three months, with potential for higher rates after reinduction.

• Interim data from a broader patient set expected in late 2024.

• Durability of response and safety profile are key differentiators.

• Systemic dosing could transform treatment workflow and patient experience.

Competitive landscape and administration

• NMIBC is a prevalent, chronic cancer with high recurrence rates.

• TARA-002 offers a simpler, faster administration compared to competitors.

• No overlapping toxicities with other monotherapies.

• Maintenance and reinduction strategies are central to long-term efficacy.

• Systemic administration avoids risks like sepsis or cytokine storm.